Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
The sales slump endured by the medical industry as the economic crisis hit may be over, according to Johnson & Johnson CEO William Weldon.
A federal judge rules 2 of Johnson & Johnson’s (NYSE:JNJ) stent patents invalid, handing a win to Medtronic, Abbott and Boston Scientific in the latest round of an ongoing legal scrimmage over drug-eluting stent technology.
Analysts warned against reading too much into poll results from a 1-day conference of cardiovascular leaders on the recall of St. Jude Medical’s (NYSE:STJ) Riata defibrillator leads, as the company looks to limit the collateral damage to its Durata lead.
Sanovas expands its California headquarters and opens a new manufacturing facility in preparation for an FDA bid and hopeful commercial launch.
A whistleblower lawsuit accuses 5 Pennsylvania cardiologists with defrauding Medicare by performing unnecessary cardiac procedures.
The FDA’s Center for Devices & Radiological Health announces its strategic priorities for 2012, including final versions of all guidance documents, guidelines for acceptable clinical data from foreign countries, streamlining the recall process and creating a framework for post-market surveillance.
Johnson & Johnson (NYSE:JNJ) subsidiary Depuy Orthopaedics decides to stop selling all custom devices following an FDA letter warning the company to file new PMA and 510(k) applications for several components.